Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels

Arthritis Research and Therapy

Volumn 16, Issue 2, 2014, Pages

  Jones, Jonathan D ^a   Hamilton, B J ^a   Challener, Gregory J ^a   de Brum Fernandes, Artur J ^b   Cossette, Pierre ^b   Liang, Patrick ^b   Masetto, Ariel ^b   Ménard, Henri A ^c   Carrier, Nathalie ^b   Boyle, David L ^d   Rosengren, Sanna ^e   Boire, Gilles ^b   Rigby, William F C ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^c RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Halozyme Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CITRULLINATED PEPTIDE ANTIBODY; CXCL13 CHEMOKINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PEPTIDE ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CXCL13 PROTEIN, HUMAN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CROSS-SECTIONAL STUDY; DAS28; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; ADOLESCENT; BLOOD; COHORT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE ACTIVITY; GENE DOSAGE; HUMORAL IMMUNITY; SEROLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BIOMARKERS; CHEMOKINE CXCL13; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; RHEUMATOID FACTOR; YOUNG ADULT;

EID: 84901634893     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4552     Document Type: Article

References (22)

1. Arend WP, Firestein GS. Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Nat Rev Rheumatol 2012, 8:573-586. 10.1038/nrrheum.2012.134, 22907289.
2. Williams DG, Moyes SP, Mageed RA. Rheumatoid factor isotype switch and somatic mutation variants within rheumatoid arthritis synovium. Immunology 1999, 98:123-136. 10.1046/j.1365-2567.1999.00841.x, 2326907, 10469243.
3. Humby F, Bombardieri M, Manzo A, Kelly S, Blades MC, Kirkham B, Spencer J, Pitzalis C. Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med 2009, 6:e1.
4. Luther SA, Lopez T, Bai W, Hanahan D, Cyster JG. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 2000, 12:471-481. 10.1016/S1074-7613(00)80199-5, 10843380.
5. Ansel KM, Ngo VN, Hyman PL, Luther SA, Forster R, Sedgwick JD, Browning JL, Lipp M, Cyster JG. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000, 406:309-314. 10.1038/35018581, 10917533.
6. Gunn MD, Ngo VN, Ansel KM, Ekland EH, Cyster JG, Williams LT. A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1. Nature 1998, 391:799-803. 10.1038/35876, 9486651.
7. Manzo A, Vitolo B, Humby F, Caporali R, Jarrossay D, Dell'Accio F, Ciardelli L, Uguccioni M, Montecucco C, Pitzalis C. Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint. Arthritis Rheum 2008, 58:3377-3387. 10.1002/art.23966, 18975336.
8. Carlsen HS, Baekkevold ES, Morton HC, Haraldsen G, Brandtzaeg P. Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood 2004, 104:3021-3027. 10.1182/blood-2004-02-0701, 15284119.
9. Takemura S, Braun A, Crowson C, Kurtin PJ, Cofield RH, O'Fallon WM, Goronzy JJ, Weyand CM. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001, 167:1072-1080. 10.4049/jimmunol.167.2.1072, 11441118.
10. Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum 2008, 58:2257-2267. 10.1002/art.23667, 18668547.
11. Rosengren S, Wei N, Kalunian KC, Kavanaugh A, Boyle DL. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford) 2011, 50:603-610. 10.1093/rheumatology/keq337, 21098574.
12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
13. Rigby WF, Wu YL, Zan M, Zhou B, Rosengren S, Carlson C, Hilton W, Yu CY. Increased frequency of complement C4B deficiency in rheumatoid arthritis. Arthritis Rheum 2012, 64:1338-1344. 10.1002/art.33472, 3775471, 22076784.
14. Carrier N, Cossette P, Daniel C, de Brum-Fernandes A, Liang P, Ménard HA, Boire G. The DERAA HLA-DR alleles in patients with early polyarthritis: protection against severe disease and lack of association with rheumatoid arthritis autoantibodies. Arthritis Rheum 2009, 60:698-707. 10.1002/art.24353, 19248090.
15. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Huizinga TW, Toes RE, de Vries RR. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 2006, 54:1117-1121. 10.1002/art.21739, 16572446.
16. Sellam J, Rouanet S, Hendel-Chavez H, Miceli-Richard C, Combe B, Sibilia J, Loët X, Tebib J, Jourdan R, Dougados M, Taoufik Y, Mariette X. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2013, 65:2253-2261. 10.1002/art.38023, 23740460.
17. Meeuwisse CM, van der Linden MP, Rullmann TA, Allaart CF, Nelissen R, Huizinga TW, Garritsen A, Toes RE, van Schaik R, van der Helm-van Mil AH. Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. Arthritis Rheum 2011, 63:1265-1273. 10.1002/art.30273, 21305530.
18. Bugatti S, Manzo A, Benaglio F, Klersy C, Vitolo B, Todoerti M, Sakellariou G, Montecucco C, Caporali R. Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs. Arthritis Res Ther 2012, 14:R34. 10.1186/ar3742, 3392832, 22336440.
19. Finch DK, Ettinger R, Karnell JL, Herbst R, Sleeman MA. Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease. Eur J Clin Invest 2013, 43:501-509. 10.1111/eci.12063, 23517338.
20. Shi K, Hayashida K, Kaneko M, Hashimoto J, Tomita T, Lipsky PE, Yoshikawa H, Ochi T. Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol 2001, 166:650-655. 10.4049/jimmunol.166.1.650, 11123349.
21. Cantaert T, Kolln J, Timmer T, van der Pouw Kraan TC, Vandooren B, Thurlings RM, Cañete JD, Catrina AI, Out T, Verweij CL, Zhang Y, Tak PP, Baeten D. B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis. J Immunol 2008, 181:785-794. 10.4049/jimmunol.181.1.785, 18566445.
22. Thurlings RM, Wijbrandts CA, Mebius RE, Cantaert T, Dinant HJ, van der Pouw-Kraan TC, Verweij CL, Baeten D, Tak PP. Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. Arthritis Rheum 2008, 58:1582-1589. 10.1002/art.23505, 18512774.